Among 811 evaluable patients, 578 (71.3%) were refractory to triple classes of routine MM medications (i.e., PI, IMID, and anti-CD38 monoclonal antibody) and the median prior line of therapy ranged from four to eight. This evidence concerns the gene CD38 and Miyoshi myopathy.